| 000 | 01104nam 2200313 4500 | ||
|---|---|---|---|
| 001 | 659503 | ||
| 005 | 20221110163735.0 | ||
| 010 | _bBrochado | ||
| 090 | _a659503 | ||
| 100 | _a20221110d1976 k||y0pory5003 ba | ||
| 101 | 0 | _aeng | |
| 102 | _aUS | ||
| 141 |
_5BPARLSR _af a0bbb |
||
| 200 | 1 |
_aAdriamycin _e(Doxorubicin Hydrochloride) for injction current clinical experience in bronchogenic carcinoma _fAdria Laboratories Inc. |
|
| 210 |
_aWilmington, Delaware _cAdria Laboratories Inc. _dcop.1976 |
||
| 215 |
_a31 p. _cil. _d28 cm |
||
| 512 | 1 | _aAdriamycin (doxorubicin HCI) for injection in Bronchogenic carcinonma | |
| 517 | 1 | _aCurrent clinical experience in bronchogenic carcinoma | |
| 606 | _aMedicamentos | ||
| 606 | _aCancro do Pulmão | ||
| 606 | _aProdutos Farmacêuticos | ||
| 606 |
_aFarmácias _xinvestigação |
||
| 606 | _aEnsaios clínicos | ||
| 675 | _a615.12 | ||
| 675 | _a615.2A/ZAdriamycin) | ||
| 675 | _a616.24-006 | ||
| 710 | 0 | 2 | _aAdria Laboratories Inc |
| 990 | _cMON | ||